XOMA earns $9M milestone on FDA approval of Day One's OJEMDA for pediatric low-grade glioma

XOMA Royalty Corp

XOMA earned $9M milestone from FDA accelerated approval of Day One's OJEMDA (tovorafenib) for relapsed/refractory BRAF-altered pLGG.
XOMA is entitled to a mid-single digit royalty on global OJEMDA sales; it is the first FDA-approved type II RAF inhibitor for this indication.
XOMA acquired rights in March 2021 from Viracta for $13.5M upfront, including $54M in potential milestones and royalties.
CEO Owen Hughes called the milestone a watershed event for children with BRAF-altered low-grade glioma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.